ImmunityBio
IBRX
IBRX
200 hedge funds and large institutions have $212M invested in ImmunityBio in 2024 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 71 increasing their positions, 41 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
more ownership
Funds ownership: →
17% less call options, than puts
Call options by funds: $8.21M | Put options by funds: $9.86M
17% less capital invested
Capital invested by funds: $256M → $212M (-$43.8M)
Holders
200
Holding in Top 10
–
Calls
$8.21M
Puts
$9.86M
Top Buyers
| 1 | +$7.69M | |
| 2 | +$7.68M | |
| 3 | +$7.2M | |
| 4 |
Morgan Stanley
New York
|
+$4.5M |
| 5 |
BlackRock
New York
|
+$4.42M |
Top Sellers
| 1 | -$4.63M | |
| 2 | -$3.28M | |
| 3 | -$2.26M | |
| 4 |
D.E. Shaw & Co
New York
|
-$1.93M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$1.51M |